Personally I think its important we get FDA nod for early data of AXAL, I think this is holding a lot up at the moment in relation to any deal or IST’s that are being worked on.
From WSJ: “MRK is searching for small and midsize deals, including more transactions aimed at expanding its portfolio of cancer treatments beyond Keytruda.”
So, question is: Does Merck consider Advaxis as a target for a deal?
Not sure. But long time investors are going to lose money even if MRK decides to buy ADXS.